DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, will present new findings that showcase the benefits of its glucose biosensing technology for people with all types of diabetes and ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
DexCom (NASDAQ:DXCM) is gearing up to announce its quarterly earnings on Thursday, 2026-02-12. Here's a quick overview of what investors should know before the release. Analysts are estimating that ...
People have been riding the GLP-1 wave to achieve quick and significant weight loss. But given the drug’s effect on controlling type 2 diabetes, it’s no surprise that DexCom CEO Jake Leach wants to ...
Dexcom is already working on its G8 sensor for continuous glucose monitoring (CGM). But before you get too excited, the product is still a couple of years out, CEO Jake Leach told MD+DI during the J.P ...
Hosted on MSN
5 best tutorials to master drawing clothes
Looking to improve your fashion drawing skills? These 5 tutorials are the best way to master drawing clothes—whether you're starting from scratch or looking to level up your technique! #DrawingClothes ...
The CGM provides real-time glucose readings for 15.5 days. “As a disabled veteran living with Type 2 diabetes, becoming a grandfather has given me a powerful new reason to take charge of my health,” ...
LOS ANGELES, Nov. 20, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against DexCom, Inc. (“DexCom” or “the Company”) (NASDAQ: DXCM) for violations of §§10(b) ...
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
It's been a tough year for DexCom (NASDAQ: DXCM), whose stock price is down 25% since the start of 2025. It's a surprising performance, given that the overall stock market has been doing well; you ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results